Pacira Sells iovera to Zimmer Biomet in Up to $140M Deal to Focus on Drug Growth

Key Facts

In a trend of biotech firms narrowing their focus, Pacira Biosciences (PCRX) has agreed to sell its iovera cryoanalgesia franchise to Zimmer Biomet (ZBH) in a deal valued at up to $140 million. According to Zacks reports, the divestiture is intended to allow Pacira to concentrate resources on biopharmaceutical development and streamline operations. The transaction is expected to close in the second half of the year, subject to regulatory approvals.

The move is part of a broader restructuring in the biotech sector, as companies shed non-core assets to improve efficiency. For Zimmer Biomet, the iovera technology—used for post-surgical pain relief—bolsters its orthopedics portfolio. Per market data, PCRX closed at $25.37 on June 30, 2026, while ZBH closed at $86.09, both showing limited volatility.

Investors will watch the deal's impact on both companies’ financial performance in coming quarters. For Pacira, the exit could improve cash flow and fund clinical trials for new therapies. Zimmer Biomet gains a complementary pain management tool. Currently, PCRX trades near its daily low of $24.66, a potential support level. No direct catalysts appear on the economic calendar for the next seven days, but Q2 earnings announcements will provide the next key catalysts for both stocks.